Efficacy of intravitreal bevacizumab after unresponsive treatment with intravitreal ranibizumab

• DOI: 10.3129/i10-095
• Publication Date: 2013-10-08T14:14:41Z
• Authors: Arghavan Almony; Azad Mansouri; Gaurav K. Shah; Kevin J. Blinder
• Keywords: Male; Vascular Endothelial Growth Factor A; Visual Acuity; Antibodies, Monoclonal; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Choroidal Neovascularization; 3. Good health; Bevacizumab; Macular Degeneration; 03 medical and health sciences; Treatment Outcome; 0302 clinical medicine; Ranibizumab; Intravitreal Injections; Retreatment; Humans; Female; Treatment Failure; Fluorescein Angiography; Tomography, Optical Coherence; Follow-Up Studies; Retrospective Studies

To evaluate visual outcomes of eyes with choroidal neovascular membrane secondary to age-related macular degeneration that were initially treated with intravitreal ranibizumab then switched to intravitreal bevacizumab due to treatment failure.Retrospective chart review.Fifty eyes of 50 patients presenting to the Barnes Retina Institute.Patients unresponsive to treatment with intravitreal ranibizumab were switched to intravitreal bevacizumab. Main outcome measures included number of intravitreal injections, visual acuity (VA), and resolution of leakage. Mean follow-up was 6 months after the final intravitreal bevacizumab injection. On average, each patient received 3.5 ranibizumab injections and 2.5 bevacizumab injections. Each patient received an average of 6 injections.Resolution of leakage on fluorescein angiography and optical coherence tomography was achieved in 44 eyes (88%). Initial VA ranged from 20/30 to counting fingers (CF) (median VA 20/125). Final VA ranged from 20/20 to CF (median VA 20/100). Change in VA varied from loss of 2 lines to gain of 4 lines, but overall, remained stable (average gain 0.3 lines). Eighteen eyes (36%) had a final VA of ≥ 20/50 and 18 eyes (36%) had a final VA of ≤20/200.Treatment with intravitreal bevacizumab may be effective, as measured by visual and anatomic criteria, in patients who are unresponsive to treatment with intravitreal ranibizumab.